These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34249954)

  • 41. Evaluation of the bioactive and total transforming growth factor β1 levels in primary myelofibrosis.
    Campanelli R; Rosti V; Villani L; Castagno M; Moretti E; Bonetti E; Bergamaschi G; Balduini A; Barosi G; Massa M
    Cytokine; 2011 Jan; 53(1):100-6. PubMed ID: 20801055
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The value of bone marrow, liver, and spleen imaging in diagnosis, prognostication, and follow-up monitoring of myeloproliferative neoplasms: a systematic review.
    Slot S; van de Donk NWCJ; Otten RHJ; Boden BJH; Zijlstra J; Raijmakers PGHM; Zweegman S
    Cancer Imaging; 2021 Apr; 21(1):36. PubMed ID: 33879266
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology.
    Dehqanzada ZA; Storrer CE; Hueman MT; Foley RJ; Harris KA; Jama YH; Shriver CD; Ponniah S; Peoples GE
    Oncol Rep; 2007 Mar; 17(3):687-94. PubMed ID: 17273752
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
    Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
    Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Longitudinal Cytokine Profiling Identifies GRO-α and EGF as Potential Biomarkers of Disease Progression in Essential Thrombocythemia.
    Øbro NF; Grinfeld J; Belmonte M; Irvine M; Shepherd MS; Rao TN; Karow A; Riedel LM; Harris OB; Baxter EJ; Nangalia J; Godfrey A; Harrison CN; Li J; Skoda RC; Campbell PJ; Green AR; Kent DG
    Hemasphere; 2020 Jun; 4(3):e371. PubMed ID: 32647796
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
    Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
    J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
    Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of inflammation in the biology of myeloproliferative neoplasms.
    Koschmieder S; Chatain N
    Blood Rev; 2020 Jul; 42():100711. PubMed ID: 32505517
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differential MMP and TIMP production by human marrow and peripheral blood CD34(+) cells in response to chemokines.
    Janowska-Wieczorek A; Marquez LA; Dobrowsky A; Ratajczak MZ; Cabuhat ML
    Exp Hematol; 2000 Nov; 28(11):1274-85. PubMed ID: 11063876
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cycling status of CD34+ cells mobilized into peripheral blood of healthy donors by recombinant human granulocyte colony-stimulating factor.
    Lemoli RM; Tafuri A; Fortuna A; Petrucci MT; Ricciardi MR; Catani L; Rondelli D; Fogli M; Leopardi G; Ariola C; Tura S
    Blood; 1997 Feb; 89(4):1189-96. PubMed ID: 9028941
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro study of matrix metalloproteinase/tissue inhibitor of metalloproteinase production by mesenchymal stromal cells in response to inflammatory cytokines: the role of their migration in injured tissues.
    Tondreau T; Meuleman N; Stamatopoulos B; De Bruyn C; Delforge A; Dejeneffe M; Martiat P; Bron D; Lagneaux L
    Cytotherapy; 2009; 11(5):559-69. PubMed ID: 19551542
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum procalcitonin in Philadelphia-negative myeloproliferative neoplasms.
    Krečak I; Peran N; Lapić I; Gverić-Krečak V; Krečak F; Rončević P; Duraković N
    Wien Klin Wochenschr; 2021 Jan; 133(1-2):62-64. PubMed ID: 32300883
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib.
    Mikulski D; Robak P; Perdas E; Węgłowska E; Łosiewicz A; Dróżdż I; Jarych D; Misiewicz M; Szemraj J; Fendler W; Robak T
    J Clin Med; 2021 Dec; 11(1):. PubMed ID: 35011853
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Organ Stiffness in the Work-Up of Myelofibrosis and Philadelphia-Negative Chronic Myeloproliferative Neoplasms.
    Benedetti E; Tavarozzi R; Morganti R; Bruno B; Bramanti E; Baratè C; Balducci S; Iovino L; Ricci F; Ricchiuto V; Buda G; Galimberti S
    J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32650390
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Remodeling the Bone Marrow Microenvironment - A Proposal for Targeting Pro-inflammatory Contributors in MPN.
    Jutzi JS; Mullally A
    Front Immunol; 2020; 11():2093. PubMed ID: 32983162
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms.
    Yonal-Hindilerden I; Daglar-Aday A; Akadam-Teker B; Yilmaz C; Nalcaci M; Yavuz AS; Sargin D
    J Blood Med; 2015; 6():157-75. PubMed ID: 26082670
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
    Agarwal MB; Malhotra H; Chakrabarti P; Varma N; Mathews V; Bhattacharyya J; Seth T; Gayathri K; Menon H; Subramanian PG; Sharma A; Bhattacharyya M; Mehta J; Vaid AK; Shah S; Aggarwal S; Gogoi PK; Nair R; Agarwal U; Varma S; Prasad SV; Manipadam MT
    Indian J Med Paediatr Oncol; 2015; 36(1):3-16. PubMed ID: 25810569
    [TBL] [Abstract][Full Text] [Related]  

  • 58. TLR4 and RAGE conversely mediate pro-inflammatory S100A8/9-mediated inhibition of proliferation-linked signaling in myeloproliferative neoplasms.
    Kovačić M; Mitrović-Ajtić O; Beleslin-Čokić B; Djikić D; Subotički T; Diklić M; Leković D; Gotić M; Mossuz P; Čokić VP
    Cell Oncol (Dordr); 2018 Oct; 41(5):541-553. PubMed ID: 29946821
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intrathecal cytokine profile in neuropathy with anti-neurofascin 155 antibody.
    Ogata H; Zhang X; Yamasaki R; Fujii T; Machida A; Morimoto N; Kaida K; Masuda T; Ando Y; Kuwahara M; Kusunoki S; Nakamura Y; Matsushita T; Isobe N; Kira JI
    Ann Clin Transl Neurol; 2019 Nov; 6(11):2304-2316. PubMed ID: 31657126
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations.
    Boveri E; Passamonti F; Rumi E; Pietra D; Elena C; Arcaini L; Pascutto C; Castello A; Cazzola M; Magrini U; Lazzarino M
    Br J Haematol; 2008 Jan; 140(2):162-8. PubMed ID: 18028479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.